Phase 2a trial results show laromestrocel (Lomecel-B™) improves cognitive function and brain volume in mild Alzheimer's disease patients. Longeveron Inc. announced positive results from its Phase 2a ...

"HLHS is a devastating disease for patients and their families, so I am impressed and very encouraged to see the continued long-term survival of patients treated with Lomecel-BTM in the ELPIS I study, ...

MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic ...

Lomecel-B™ is now known as laromestrocel, a cellular therapy for Alzheimer's and hypoplastic left heart syndrome, following WHO approval. Longeveron Inc. has announced that its cellular therapy ...

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as ...

Lomecel-B is delivered via intramyocardial injection. The Food and Drug Administration (FDA) has granted Fast Track designation to Lomecel-B ™, an investigational allogeneic, bone marrow-derived ...

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage ...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Longeveron Inc. (NASDAQ: LGVN) is optimistic ...

Longeveron Inc LGVN announced the publication of Phase 1 trial results of Lomecel-B on patients with mild Alzheimer's disease (AD) in the Alzheimer's & Dementia journal. The 33-subject trial met its ...

MIAMI, Oct. 27, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that its positive long-term ...